- Worldwide revenue of $378.7 million, an increase of 18.4% from third quarter 2023
- GAAP fully diluted earnings per share of $1.79, compared to $1.88 in the third quarter of 2023. Adjusted fully diluted earnings per share of $1.70 compared to $1.47 in the third quarter of 2023
- Company narrows full year 2024 revenue and fully diluted earnings per share guidance towards higher end of the previously issued guidance
- Company applauds CMS' CY25 rule to improve payment for specialized diagnostic radiopharmaceuticals, including PYLARIFY, advancing patient access and care
- Company announced that it expanded its Alzheimer's disease radiodiagnostics portfolio with NAV-4694, a novel, next generation late-stage beta-amyloid imaging agent
Full Year 2024 Financial Guidance
Guidance Issued November 6, 2024 | Guidance Issued July 31, 2024 | |
FY 2024 Revenue | $1.51 billion - $1.52 billion | $1.50 billion - $1.52 billion |
FY 2024 Adjusted Fully Diluted EPS | $6.65 - $6.70 | $6.60 - $6.70 |
Conference Call and Webcast
As previously announced, the Company will host a conference call and webcast on Wednesday, November 6, 2024, at 8:00 a.m. ET. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events.
A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.
The conference call will include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com.
The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.